An Alternative to Dalteparin for Cancer-Related VTE
Dr David Kerr discusses a promising new study suggesting that oral edoxaban may be substituted for daily subcutaneous dalteparin in cancer patients who have had a venous thromboembolism.
Source: Medscape Oncology - Category: Cancer & Oncology Authors: Medscape Source Type: podcasts